<DOC>
	<DOCNO>NCT00352690</DOCNO>
	<brief_summary>This study intend evaluate role paclitaxel poliglumex carboplatin treatment unresectable Stage III non-small cell lung cancer along radiation therapy multi-institutional trial . Consolidation chemotherapy paclitaxel poliglumex carboplatin follow completion chemoradiation .</brief_summary>
	<brief_title>A Phase II Study Radiation Therapy , Paclitaxel Poliglumex , Carboplatin Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically document NSCLC , include squamous cell carcinoma , adenocarcinoma ( include bronchoalveolar cell ) , large cell anaplastic carcinoma ( include giant clear cell carcinoma ) . Eligible Disease Stages : Inoperable IIIA Selected IIIB Local radiation oncologist must approve patient eligibility prior entry study . Patients must measurable disease . Prior Therapy : ≥ 2 week since formal exploratory thoracotomy . No prior chemotherapy radiation therapy NSCLC . ECOG performance status 01 Required Initial Laboratory Values ( must submit within 16 day prior registration ) : Granulocytes ≥ 1,500/µl Platelets ≥ 100,000/µl Calculated Creatinine Clearance ≥ 20 cc/min Bilirubin &lt; 1.5 mg/dl AST ( SGOT ) &lt; 2 x ULN INR &gt; 0.8 &lt; 1.2* *Values apply exclusively patient treat warfarin . Values patient treat warfarin fall within follow therapeutic range : &gt; 2.0 &lt; 3.0 . Currently active second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse . Pregnant nursing significant risk fetus/infant . Age &lt; 18 year . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . No HIVpositive patient receive combination antiretroviral therapy . Because patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy Onesecond force expiratory volume ( FEV1 ) &lt; 50 % hemoglobincorrected carbon monoxide diffusion capacity ( DLCO ) &lt; 50 % predict , measure within 21 day study entry Symptoms esophageal dysfunction ( dysphagia , odynophagia , inability swallow solid food ) within 4 week prior study randomization . Patients must require prophylactic placement percutaneous enterogastrostomy ( PEG ) tube nonoral nutritional supplement method Weight loss &gt; 10 % past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>